Latest News
“Luminal B tumors are a type of hormone receptor-positive tumors that tend to be a bit more faster growing,” Dr. Maryam Lustberg, the director of the Center for Breast Cancer at Yale Cancer Center and Smilow Cancer Hospital, stated. “They are still very much driven by estrogen-based pathways as luminal A tumors but are sometimes treated with more intensive type of systemic therapies including maximal estrogen suppression, targeted therapies and sometimes chemotherapy.”
- April 10, 2024Source: SurvivorNet
“In clinical trials, tumors with Her2 overexpression had higher chances of responding to therapy and stabilizing the disease process,” says Dr. Maryam Lustberg, director of the Center for Breast Cancer at Smilow Cancer Hospital and Yale Cancer Center. “The right treatment will stabilize disease process and will also have good quality of life and an acceptable side effect profile.”
- April 10, 2024Source: Everyday Health
Clinical trials are the way that doctors find out whether a new treatment is better than or equal to the currently available options. If you participate in a study you will most likely receive really great care. “There are more eyes on you,” explains Maryam Lustberg, MD, MPH, the director of the Center for Breast Cancer at Yale Cancer Center in New Haven, Connecticut
- April 08, 2024
Despite smoking being a significant health risk leading to lung cancer, the disease remains a considerable concern for those who have never smoked. While cigarettes remain a dominant contributor, there are also other risk elements such as exposure to environmental toxins like radon gas, second-hand smoke and occupational risks.
- March 20, 2024
Declines in the death rate for breast cancer have furthered overall progress in cancer mortality.
- March 20, 2024
Marcella Nunez-Smith is laser-focused on eliminating inequities among marginalized people.
- January 31, 2024Source: Vox
Today, Explained [a podcast] digs into the stigma associated with prostate cancer diagnosis like Defense Secretary Lloyd Austin’s, and the fear many men have of the exam itself.
- January 25, 2024Source: Urology Times
Michael Leapman, MD, MHS, shares background and key findings from the study, “Temporal and regional patterns of prostate cancer positron emission tomography imaging among commercial insurance beneficiaries in the United States.”
- December 08, 2023
New research illustrates remarkably lower use of immediate breast reconstruction in older women of Asian descent.
- November 14, 2023
In a Q&A, Ilana Richman, MD, MHS, assistant professor of medicine (general medicine), discusses why overdiagnosis is a concern, the challenges of assessing the benefit of new screening technologies, and the risks and benefits people should weigh when considering preventative screening.